Characteristic | Number (%) |
---|---|
Diffuse: limited skin involvement | 20:73 (22:78) |
Anti-centromere antibodies | 30 (32) |
Anti-topoisomerase antibodies | 22 (24) |
Anti-RNA polymerase III antibodies | 3 (3) |
Pathological cineradiography | 70 (75) |
Immunosuppressive therapy | 36 (39) |
Median (IQR) | |
Disease duration (years) | 7 (2 to 13) |